Tuesday, 13 January 2026
  
Login

Australia's most trusted
source of pharma news

Tuesday, 13 January 2026
News

TGA kicks off with first-in-class nod

Posted 12 January 2026 AM

2026 has kicked off with the ARTG listing of a first-in-class drug to treat an ultra-rare disease.

Takeda has scored an ARTG listing for its recombinant ADAMTS13 (rADAMTS13) enzyme replacement therapy Adzynma, which has been listed for the treatment of ADAMTS13 deficiency in patients with congenital thrombotic thrombocytopenic purpura (cTTP), in all age groups. It's the first recombinant ADAMTS13 replacement therapy.

To see the whole article, please login

Popular

New Year, new pharma on the PBS
Job moves mark start of 2026
TGA kicks off with first-in-class nod
'No deal' drugs face PBAC review
Latest Jobs
MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe
 
© 2003 - 2026 Lush Media | Privacy Statement | Subscribe to Pharma in Focus
home